1372526-38-9

Basic information

• Product Name: (S)-(4-chlorophenyl)(3-((1-(2-hydroxyoctyl)piperidin-4-yl)methoxy)phenyl)methanone
• Synonyms: (S)-(4-chlorophenyl)(3-((1-(2-hydroxyoctyl)piperidin-4-yl)methoxy)phenyl)methanone
• CAS NO: 1372526-38-9
• Molecular Weight: 458.041
• Mol File: 1372526-38-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-(4-chlorophenyl)(3-((1-(2-hydroxyoctyl)piperidin-4-yl)methoxy)phenyl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-(4-chlorophenyl)(3-((1-(2-hydroxyoctyl)piperidin-4-yl)methoxy)phenyl)methanone(1372526-38-9)
• EPA Substance Registry System: (S)-(4-chlorophenyl)(3-((1-(2-hydroxyoctyl)piperidin-4-yl)methoxy)phenyl)methanone(1372526-38-9)

Safety Data

• Hazardous Substances Data: 1372526-38-9(Hazardous Substances Data)

Upstream product

• 122-01-0 4-chloro-benzoyl chloride 
• 122334-37-6 4-chloro-N-methoxy-N-methylbenzamide 
• 62810-39-3 (4-chlorophenyl)(3-hydroxyphenyl)methanone 
• 32363-45-4 (4-chlorophenyl)(3-methoxyphenyl)methanone 
• 1372526-58-3 (4-chlorophenyl)(3-(piperidin-4-ylmethoxy)phenyl)methanone 
• 2984-50-1 (2S)-2-hexyloxirane 
• 1372526-57-2 tert-butyl 4-{[3-(4-chlorobenzoyl)phenoxy]methyl}-piperidine-1-carboxylate 

Downstream Products

• 1372526-40-3 (S)-1-(4-((3-(4-chlorobenzoyl)phenoxy)methyl)piperidin-1-yl)octan-2-yl carbamate 

Relevant articles and documents

Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis

Aurachin RE (1) is a strong antibiotic that was recently found to possess 1,4-dihydroxy-2-naphthoate prenyltransferase (MenA) and bacterial electron transport inhibitory activities. Aurachin RE is the only molecule in a series of aurachin natural products that has the chiral center in the alkyl side chain at C9′-position. To identify selective MenA inhibitors against Mycobacterium tuberculosis, a series of chiral molecules were designed based on the structures of previously identified MenA inhibitors and 1. The synthesized molecules were evaluated in in vitro assays, including MenA enzyme and bacterial growth inhibitory assays. We could identify novel MenA inhibitors that showed significant increase in potency of killing nonreplicating M. tuberculosis in the low oxygen recovery assay (LORA) without inhibiting other Gram-positive bacterial growth even at high concentrations. The MenA inhibitors reported here are useful new pharmacophores for the development of selective antimycobacterial agents with strong activity against nonreplicating M. tuberculosis.